GUMM - Eliminate the Common Cold Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: StockDung	10/26/2009 1:52:08 PM
	of 5582

Matrixx (MTXX) Shares Tumble as FDA Won't Reverse Position on Zicam Matrixx (MTXX) Shares Tumble as FDA Won't Reverse Position on Zicam October 26, 2009 8:24 AM EDT Shares of Matrixx Initiatives (Nasdaq: MTXX) are getting slammed this morning following an 8-K filing announcing that the FDA has now indicated that it is unwilling to reverse its position related to Zicam Cold Remedy nasal gel products. The stock has plunged more than 12% to around $4.41. Matrixx said it is currently evaluating its options. In addition, the FDA recently identified several observations of individual cases where the FDA indicated that Matrixx should have filed serious adverse event reports with the MedWatch Reporting system. The company said it is reviewing the observations and will be responding soon.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next